

TSR-011 – Patent pending



LEERINK SWANN

- Three patent families
- On both composition of matter and methods of treating certain cancer sub-populations whose tumors express mutant ALK protein
- Four U.S. patent applications (two pending, two expired)
- Two Patent Cooperation Treaty applications
- If issued, would expire in 2031 and 2032